Three things you need to know in the financial markets today from investment writer, Tony Cross.
#1. genedrive hints at potential for NHS contract win
AIM listed genedrive LON:GDR has this morning issued a statement noting that the national health regulator NICE has recommended that CYP2C19 genotyping should be used before certain treatments are performed on stroke patients. Genedrive is currently developing its own CYP2C19 test and it is currently seen as being the most cost effective solution in the space. With the company having worked closely with NICE in the past, there are clear hopes that they will be a preferred supplier here.
- UK Stock Market News: WH Smith, Sage, Smiths Group
- AIM Market Roundup: Genedrive, Image Scan, Kodal Minerals
- AIM Market Roundup: Genedrive, Idox, Diales
#2. Smiths Group’s strong Q3 sees full year guidance upped
There’s a Q3 trading update out from Smiths Group LON:SMIN this morning, noting continues strong growth and leading management to increase guidance for the full year’s organic revenue by around 10% with modest margin improvements, too. The company has now delivered eight consecutive quarters of growth.
#3. Oxford Nanopore updates from customer conference
Oxford Nanopore Technologies LON:ONT has published a note summarising the key takeaways of its annual customer conference. Perhaps unsurprisingly given its nature there is little of short term consequence here although the plan to double genome output by 100% is notable and the summary highlights some of the other innovations being deployed by the company in order to remain at the cutting edge.
